Electro-Acupuncture in Lung cancER : EALER Study

This multicentre, randomized controlled trial evaluates the effect and safety of acupuncture combing with PD-1 inhibitors plus chemotherapy in NSCLC. Participants will be randomly assigned to undergo either acupuncture or sham acupuncture concurrent with the initial four-six cycles of chemotherapy combined with PD-1 inhibitors.

Trial Details

NCT ID
NCT07337096
Phase
NA
Sponsor
Guangzhou University of Traditional Chinese Medicine
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Acupuncture
  • Sham acupuncture
  • Combination of chemotherapy and immunotherapy
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Pathologically confirmed NSCLC, with AJCC lung cancer TNM stage IV.
  • Tumor proportion score for PD-L1 \< 50%.
  • Lacks targetable gene mutations (including but not limited to EGFR mutations or ALK fusions).
  • No prior systemic therapy for advanced NSCLC (including chemotherapy, targeted therapy, or immunotherapy). Patients planned to receive first-line (…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →